|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2003-3-25
|
|
pubmed:abstractText |
Cytotoxic T lymphocytes (CTL) are key players to suppress viral load (VL) but CTL responses become compromised with progression of HIV-infection/AIDS. Some progressors develop MHC-unrestricted CTL with anti-CD4+ cytocidal activity. Immune activation status of these CTL and its significance in disease progression are unknown. To determine the relationship between VL and T cell activation, a cross-sectional study was carried out using blood samples from 13 HIV-1-infected/AIDS patients at various stages of progression and seven age-matched seronegative controls. We examined expression of HLA-DR and CD38 activation markers on purified CTL. MHC-unrestricted killing by these CTL was also evaluated against uninfected, allogeneic CD4+ T cells as well as several human cell lines. The expression of activation markers correlated inversely (rs = - 0.91, P < 0.0001) with VL of the subjects. CTL effectors of these patients killed targets expressing or lacking CD4+, independently of MHC class I recognition. Interestingly, the patients with higher VL showed an increased number of gammadeltaTCR-bearing CTL in blood and their MHC-unrestricted killing activity was blocked significantly (P < 0.01) by gammadeltaTCR-specific monoclonal antibody. CD3+ T counts of these patients were also consistently subnormal. Inverse correlation between VL and CD8+ T cell activation markers seems to be an indicator of CTL-associated immunopathogenesis in HIV patients with elevated gammadeltaCTL in the peripheral blood.
|
|
pubmed:commentsCorrections |
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-10477629,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-10546856,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-10770542,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-11294674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-11309628,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-11496243,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-11721322,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-11873002,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-12032270,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-12525619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-1418775,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-1458674,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-1829106,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-7585150,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-7805732,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-7816094,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-7822807,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8057491,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8103717,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8454874,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8620619,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8757509,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8809474,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8838701,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-8882663,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-9465488,
http://linkedlifedata.com/resource/pubmed/commentcorrection/12653846-9724793
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0009-9104
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
132
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
120-7
|
|
pubmed:dateRevised |
2009-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:12653846-Acquired Immunodeficiency Syndrome,
pubmed-meshheading:12653846-Biological Markers,
pubmed-meshheading:12653846-CD4-Positive T-Lymphocytes,
pubmed-meshheading:12653846-Case-Control Studies,
pubmed-meshheading:12653846-Cross-Sectional Studies,
pubmed-meshheading:12653846-Disease Progression,
pubmed-meshheading:12653846-HIV Infections,
pubmed-meshheading:12653846-HIV-1,
pubmed-meshheading:12653846-Hemolysis,
pubmed-meshheading:12653846-Humans,
pubmed-meshheading:12653846-Lymphocyte Activation,
pubmed-meshheading:12653846-Major Histocompatibility Complex,
pubmed-meshheading:12653846-Statistics, Nonparametric,
pubmed-meshheading:12653846-T-Lymphocytes, Cytotoxic,
pubmed-meshheading:12653846-Viral Load
|
|
pubmed:year |
2003
|
|
pubmed:articleTitle |
Virus load correlates inversely with the expression of cytotoxic T lymphocyte activation markers in HIV-1-infected/AIDS patients showing MHC-unrestricted CTL-mediated lysis.
|
|
pubmed:affiliation |
Laboratory of Immunovirology, St Justine Hospital, Montreal, Canada.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|
